Vivent Health
Registered Principal Details
Business Or Interest:
HIV/AIDS prevention, care and treatment services; sexual health, including the screening, diagnosis and treatment of sexually transmitted infections; hepatitis C prevention, care and treatment services.
Lobbying Interests:
Areas related to HIV, AIDS, public health, public health funding, medical assistance/Medicaid reimbursement and eligibility, and sexual health, including sexually transmitted infections.
HIV/AIDS prevention, care and treatment services; sexual health, including the screening, diagnosis and treatment of sexually transmitted infections; hepatitis C prevention, care and treatment services.
Lobbying Interests:
Areas related to HIV, AIDS, public health, public health funding, medical assistance/Medicaid reimbursement and eligibility, and sexual health, including sexually transmitted infections.
Contact
BK
Bill Keeton
820 N Plankinton Ave
Milwaukee, WI 53203
(414) 225-1572
bill.keeton@viventhealth.org
http://www.viventhealth.org
820 N Plankinton Ave
Milwaukee, WI 53203
(414) 225-1572
bill.keeton@viventhealth.org
http://www.viventhealth.org
Authorized Lobbyists
| Lobbyist Name | Exclusive Duties | Authorized On | Withdrawn On |
|---|
Lobbying Interests
Legislative Bills/Resolutions
Assembly Bill 465
Relating to: prohibiting gender transition medical intervention for individuals under 18 years of age.
Bill Text and History
10/6/2023
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Relating to: prohibiting gender transition medical intervention for individuals under 18 years of age.
Bill Text and History
Against
Notification Date10/6/2023
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Assembly Bill 634
Relating to: immunity for certain controlled substances offenses for aiders and aided persons.
Bill Text and History
11/29/2023
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Relating to: immunity for certain controlled substances offenses for aiders and aided persons.
Bill Text and History
For
Notification Date11/29/2023
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Assembly Bill 773
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
Bill Text and History
12/13/2023
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
Bill Text and History
For
Notification Date12/13/2023
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Assembly Bill 950
Relating to: excepting xylazine testing materials from the definition of drug paraphernalia and civil and criminal liability exemptions for distributing and administering xylazine testing products.
Bill Text and History
1/23/2024
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Relating to: excepting xylazine testing materials from the definition of drug paraphernalia and civil and criminal liability exemptions for distributing and administering xylazine testing products.
Bill Text and History
For
Notification Date1/23/2024
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Senate Bill 595
Relating to: immunity for certain controlled substances offenses for aiders and aided persons.
Bill Text and History
11/29/2023
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Relating to: immunity for certain controlled substances offenses for aiders and aided persons.
Bill Text and History
For
Notification Date11/29/2023
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Senate Bill 737
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
Bill Text and History
12/13/2023
First Communication Date
12/6/2023
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has communicated on this matter.
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
Bill Text and History
For
Notification Date12/13/2023
First Communication Date
12/6/2023
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has communicated on this matter.
Senate Bill 875
Relating to: excepting xylazine testing materials from the definition of drug paraphernalia and civil and criminal liability exemptions for distributing and administering xylazine testing products.
Bill Text and History
2023 Wisconsin Act 217
1/23/2024
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Relating to: excepting xylazine testing materials from the definition of drug paraphernalia and civil and criminal liability exemptions for distributing and administering xylazine testing products.
Bill Text and History
2023 Wisconsin Act 217
For
Notification Date1/23/2024
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Budget Bill Subjects
Biennial budget bill treatment of matter relating to
Health Services: Departmentwide
Health Services: Departmentwide
Notification Date
7/31/2023
First Communication Date
1/5/2023
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has communicated on this matter.
7/31/2023
First Communication Date
1/5/2023
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has communicated on this matter.
Total Lobbying Effort
| 2023 January - June |
2023 July - December |
2024 January - June |
Total | |
|---|---|---|---|---|
| Total Lobbying Expenditures | 2023 January - June $17,880.00 |
2023 July - December $16,513.00 |
2024 January - June $15,796.00 |
Total $50,189.00 |
| Total Hours Communicating | 2023 January - June 21.50 |
2023 July - December 10.25 |
2024 January - June 6.50 |
Total 38.25 |
| Total Hours Other | 2023 January - June 63.00 |
2023 July - December 42.50 |
2024 January - June 29.25 |
Total 134.75 |
Percent Allocation of Lobbying Effort
Legislative Bills/Resolutions
Relating to: immunity for certain controlled substances offenses for aiders and aided persons.
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total |
|---|---|---|---|---|
| 2023 January - June |
2023 July - December 5% |
2024 January - June 20% |
2024 July - December |
Total 6% |
Relating to: excepting xylazine testing materials from the definition of drug paraphernalia and civil and criminal liability exemptions for distributing and administering xylazine testing products.
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total |
|---|---|---|---|---|
| 2023 January - June |
2023 July - December 5% |
2024 January - June 10% |
2024 July - December |
Total 4% |
Relating to: immunity for certain controlled substances offenses for aiders and aided persons.
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total |
|---|---|---|---|---|
| 2023 January - June |
2023 July - December 5% |
2024 January - June 20% |
2024 July - December |
Total 6% |
Relating to: excepting xylazine testing materials from the definition of drug paraphernalia and civil and criminal liability exemptions for distributing and administering xylazine testing products.
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total |
|---|---|---|---|---|
| 2023 January - June |
2023 July - December 5% |
2024 January - June 10% |
2024 July - December |
Total 4% |
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total |
|---|---|---|---|---|
| 2023 January - June |
2023 July - December 40% |
2024 January - June 20% |
2024 July - December |
Total 16% |
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total |
|---|---|---|---|---|
| 2023 January - June |
2023 July - December 40% |
2024 January - June 20% |
2024 July - December |
Total 16% |
Budget Bill Subjects
| 2023 January - June |
2023 July - December |
2024 January - June |
2024 July - December |
Total |
|---|---|---|---|---|
| 2023 January - June 100% |
2023 July - December |
2024 January - June |
2024 July - December |
Total 49% |
Administrative Rulemaking Proceedings
No administrative rulemaking proceedings found.
Topics Not Yet Assigned A Bill Or Rule Number
No topics found.
Minor Efforts
No minor efforts found.
Other Matters
No other matters found.